Filtern
Volltext vorhanden
- ja (77)
Gehört zur Bibliographie
- ja (77)
Erscheinungsjahr
Dokumenttyp
- Artikel / Aufsatz in einer Zeitschrift (77) (entfernen)
Sprache
- Englisch (77)
Schlagworte
- PET (19)
- Positronen-Emissions-Tomografie (14)
- positron emission tomography (12)
- theranostics (11)
- CXCR4 (9)
- multiple myeloma (9)
- PET/CT (8)
- PRRT (8)
- neuroendocrine tumor (7)
- molecular imaging (6)
Institut
- Klinik und Poliklinik für Nuklearmedizin (74)
- Medizinische Klinik und Poliklinik II (18)
- Pathologisches Institut (10)
- Medizinische Klinik und Poliklinik I (9)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (8)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (8)
- Urologische Klinik und Poliklinik (4)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (3)
- Comprehensive Cancer Center Mainfranken (3)
- Institut für Pharmazie und Lebensmittelchemie (3)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (9)
- Johns Hopkins University School of Medicine (4)
- Clinical Trial Center (CTC) / Zentrale für Klinische Studien Würzburg (ZKSW) (1)
- Department of Biomedical Imaging, National Cerebral and Cardiovascular Research Center, Suita, Japan (1)
- Department of Nuclear Medicine, Kanazawa University (1)
- Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, Suita Japan (1)
- Institut for Molecular Biology and CMBI, Department of Genomics, Stem Cell Biology and Regenerative Medicine, Leopold-Franzens-University Innsbruck, Innsbruck, Austria (1)
- Johns Hopkins School of Medicine, Baltimore, MD, USA (1)
- Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, USA (1)
- Johns Hopkins University, Baltimore, MD, U.S. (1)
EU-Projektnummer / Contract (GA) number
- 701983 (21)
C-X-C-motif chemokine receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer. We have recently reported promising first-in-man experience with CXCR4-directed endoradiotherapy (ERT) in multiple myeloma (MM).
Eight heavily pretreated MM patients underwent a total of 10 ERT cycles (7 patients with 1 cycle and a single patient with 3 cycles). ERT was administered in combination with chemotherapy and autologous stem cell support. End points were occurrence and timing of adverse events, progression-free and overall survival.
ERT was overall well tolerated without any unexpected acute adverse events or changes in vital signs. With absorbed tumor doses >30-70 Gy in intra- or extramedullary lesions, significant anti-myeloma activity was observed with 1 patient achieving complete remission and 5/8 partial remission. Directly after ERT major infectious complications were seen in one patient who died from sepsis 22 days after ERT, another patient with high tumor burden experienced lethal tumor lysis syndrome. Median progression-free survival was 54 days (range, 13-175), median overall survival was 223 days (range, 13-313). During follow-up (6 patients available), one patient died from infectious complications, 2/8 from disease progression, the remaining 3/8 patients are still alive.
CXCR4-directed ERT was well-tolerated and exerted anti-myeloma activity even at very advanced stage MM with presence of extramedullary disease. Further assessment of this novel treatment option is highly warranted.